Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) from a hold rating to a buy rating in a report issued on Wednesday. Zacks Investment Research currently has $23.00 price objective on the stock.

According to Zacks, “Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. “

Several other research analysts have also issued reports on KNSA. Wedbush restated an outperform rating and issued a $31.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, September 11th. JMP Securities raised their price target on Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the stock an outperform rating in a research report on Monday, September 17th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $31.75.

Shares of NASDAQ:KNSA traded down $1.19 during midday trading on Wednesday, hitting $19.94. The company had a trading volume of 10,134 shares, compared to its average volume of 47,302. Kiniksa Pharmaceuticals has a 12 month low of $13.04 and a 12 month high of $32.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Thursday, November 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. Analysts forecast that Kiniksa Pharmaceuticals will post -2.63 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. American International Group Inc. acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth $110,000. Alps Advisors Inc. raised its stake in Kiniksa Pharmaceuticals by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 27,893 shares of the company’s stock worth $711,000 after buying an additional 6,491 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth $115,000. BlackRock Inc. acquired a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth $173,000. Finally, Bank of New York Mellon Corp acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth $435,000. 34.91% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: What is the balance sheet?

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.